242 related articles for article (PubMed ID: 19144951)
1. SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD; Isackson PJ
N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
[No Abstract] [Full Text] [Related]
2. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
Mitka M
JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
[No Abstract] [Full Text] [Related]
3. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
4. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics and drug toxicity.
Nakamura Y
N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
[No Abstract] [Full Text] [Related]
6. [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
Dendramis G
G Ital Cardiol (Rome); 2011 Mar; 12(3):182-5. PubMed ID: 21560474
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacogenetic analysis can predict adverse effects of statins].
Garwicz D; Wadelius M
Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
[No Abstract] [Full Text] [Related]
8. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
Rossi JS; McLeod HL
J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
[No Abstract] [Full Text] [Related]
9. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
10. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
[TBL] [Abstract][Full Text] [Related]
12. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.
Puccetti L; Ciani F; Auteri A
Atherosclerosis; 2010 Jul; 211(1):28-9. PubMed ID: 20347093
[No Abstract] [Full Text] [Related]
13. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
14. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
15. The genetics of statin-induced myopathy.
Ghatak A; Faheem O; Thompson PD
Atherosclerosis; 2010 Jun; 210(2):337-43. PubMed ID: 20042189
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
17. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
[TBL] [Abstract][Full Text] [Related]
19. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Generaux GT; Bonomo FM; Johnson M; Doan KM
Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
[TBL] [Abstract][Full Text] [Related]
20. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy.
Neřoldová M; Stránecký V; Hodaňová K; Hartmannová H; Piherová L; Přistoupilová A; Mrázová L; Vrablík M; Adámková V; Hubáček JA; Jirsa M; Kmoch S
Pharmacogenomics; 2016 Aug; 17(13):1405-14. PubMed ID: 27296017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
